Skip to Content

Label Changes for:

Novothyrox (levothyroxine sodium) Tablets

March 2009

Changes have been made to the PRECAUTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- March 2009


The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.

Summary View

Sections Modified


  • agents such as iron and calcium supplements and antacids can decrease the absorption of levothyroxine tablets
  • instructions for reporting side effects to FDA
  • drug-drug interaction between levothyroxine and orlistat